Skip to main content

Paul Thompson, PhD

Chief Scientific Officer at Mission Therapeutics

Location: Cambridge United Kingdom

Dr. Paul William Thompson is a PhD translational/clinical scientist and has worked in industry for more than 20 years, leading projects in target identification through to Phase 2 in many therapeutic areas, particularly neurological disorders. During his time at Mission Therapeutics, Dr. Thompson served as VP of clinical development before becoming chief scientific officer in 2H in 2020. He has been responsible for identifying, developing and transitioning to clinic USP30 inhibitors, one of which, MTX652, completed phase I studies in 2023. He currently leads the investigation of CNS USP30 inhibitor MTX325 for Parkinson’s disease, which transitions to clinic in 2024, following successful publication of key target validation data together with Harvard Medical School and Cambridge University. Prior to Mission Therapeutics, Dr. Thompson held positions as clinical science director at Ono Pharma and director of discovery medicine neurology at GSK.


Associated Grants

  • Examining the Effects of MTX325 on Mitochondrial Quality Control and the Prevention of Parkinson’s Disease Progression

    2024


  • Proof of Concept and Translational Validation of USP30 to Offset Dysfunction in the PRKN Pathway

    2021


  • Validation of USP30 as a Therapeutic Target for Parkinson's Disease Modification

    2017


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.